Mitä Predilife tekee? Predilife SA is a company specializing in predictive medicine. It was founded in Switzerland in 2011 and has since been based in Marseille, France. The company currently has around 50 employees, most of whom are scientists and doctors. The idea for Predilife SA came from the realization that many diseases can be prevented if they are detected and treated in advance. As most diseases also have a genetic component, Predilife SA focuses on the development of tests that calculate individual disease risk based on individual genetics. The business model of Predilife SA is based on the development and sale of predictive genetic tests for various diseases. The company works with health insurance companies, insurance companies, companies, as well as directly with end customers. The company believes that predictive tests represent an opportunity for many people to detect diseases early and take appropriate preventive measures. The company offers predictive tests for a range of diseases, including cancer, cardiovascular diseases, neurodegenerative diseases, and diabetes. The tests are based on state-of-the-art molecular diagnostic methods that allow for the identification of genetic changes that increase individual disease risk. The tests are conducted in specialized laboratories and interpreted by qualified doctors and geneticists. Predilife SA operates four different divisions and offers a range of predictive tests for each division: Division 1: Cancer prevention This division focuses on tests for common types of cancer such as breast, colon, and prostate cancer. The tests assess the individual risk of developing cancer and help optimize prevention and surveillance measures. Division 2: Cardiovascular diseases This division offers tests that assess the individual risk of cardiovascular diseases such as heart attack or stroke. The results are used to take targeted preventive measures. Division 3: Neurological diseases This division develops tests for neurodegenerative diseases such as Alzheimer's or Parkinson's. The results help determine individual risk and take appropriate preventive measures. Division 4: Diabetes This division offers tests that assess the individual risk of type 2 diabetes. The results are used to take targeted preventive measures. In addition to predictive tests, Predilife SA operates its own research department that focuses on the development of new predictive tests and the further development of existing tests. The company collaborates with leading scientists and institutions worldwide. Overall, Predilife SA aims to make predictive medicine accessible to as many people as possible. The company relies on state-of-the-art technologies and high professional competence. Predilife on yksi Eurpooliin suosituimmista yhtiöistä.